Eli Lilly is paying $40 million up front for rights to a Confo Therapeutics drug in Phase 1 testing as a potential treatment for neuropathic pain. Confo develops drugs that target G-protein coupled receptors.
Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The companies will test Biofourmis' sensor and artificial intelligence system in a clinical trial of more than 120 women with endometriosis.
The US-based subsidiary will bring together existing research and development and manufacturing businesses in the US, India and Switzerland.
The company plans to use the financing to support development of its drug, KarXT, in schizophrenia and indications like pain.
The Digital Health Breakthrough Network, which is a partnership between HITLAB and NYCEDC, recently announced its third cohort of startups. The class includes Altopax, Navimize, PainQx and Tatch.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Philadelphia startup PainQx has software that uses EEG data to objectively measure pain in patients. The current system of measuring pain is, after all, rudimentary at best.